Current status and research progress of the association between metabolic syndrome and atherosclerotic disease

doi:10.3877/cma.j.issn.2095-9605.2023.04.007

Abstract

Abstract:

Metabolic syndrome (MetS) is a collection of metabolic abnormalities that are strongly associated with health issues such as arteriosclerotic cardiovascular disease (ASCVD) and type 2 diabetes mellitus (T2DM). With the growing awareness of MetS and the increasing precision of its diagnostic criteria, the widespread prevalence of MetS is indisputable. The mechanisms behind the association of MetS with atherosclerotic diseases involve oxidative stress (OS), insulin resistance (IR), long-term chronic inflammation, and dyslipidemia, among many others. This paper will delve into the link between MetS and atherosclerosis and its various aspects. In addition, future studies need to clarify the specific mechanisms by which MetS leads to atherosclerosis, evaluate potential biomarkers, and continue to optimize therapeutic strategies.

Key words: Metabolic syndrome, Atherosclerosis, Arteriosclerotic cardiovascular disease, Peripheral arterial disease, Type 2 diabetes mellitus, Obesity

Hao Qian, Zhenzhen Li. Current status and research progress of the association between metabolic syndrome and atherosclerotic disease[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(04): 267-273.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2023.04.007

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2023/V09/I04/267

References 52

[1]	Paixão TM, Teixeira LR, Andrade CAF, et al. Systematic Review and Meta-Analysis of Metabolic Syndrome and Its Components in Latino Immigrants to the USA [J]. Int J Environ Res Public Health, 2023, 20(2): 1307.
[2]	Huang Y, Zhang L, Wang Z, et al. The prevalence and characteristics of metabolic syndrome according to different definitions in China: a nationwide cross-sectional study, 2012-2015 [J]. BMC Public Health, 2022, 22(1): 1869.
[3]	Kong P, Cui ZY, Huang XF, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention [J]. Signal Transduct Target Ther, 2022, 7(1): 131.
[4]	Xu JJ, Song Y, Jiang P, et al. Eff ects of metabolic syndrome on onset age and long-term outcomes in patients with acute coronary syndrome [J]. World J Emerg Med, 2021, 12(1): 36-41.
[5]	Opio J, Wynne K, Attia J, et al. Overweight or obesity increases the risk of cardiovascular disease among older Australian adults, even in the absence of cardiometabolic risk factors: a Bayesian survival analysis from the Hunter Community Study [J]. Int J Obes (Lond), 2023, 47(2): 117-125.
[6]	Iso H, Cui R, Takamoto I, et al. Risk Classification for Metabolic Syndrome and the Incidence of Cardiovascular Disease in Japan With Low Prevalence of Obesity: A Pooled Analysis of 10 Prospective Cohort Studies [J]. J Am Heart Assoc, 2021, 10(23): e020760.
[7]	Alshammary AF, Alharbi KK, Alshehri NJ, et al. Metabolic Syndrome and Coronary Artery Disease Risk: A Meta-Analysis of Observational Studies [J]. Int J Environ Res Public Health, 2021, 18(4): 1773.
[8]	Li X, Li X, Lin H, et al. Metabolic syndrome and stroke: A meta-analysis of prospective cohort studies [J]. J Clin Neurosci, 2017, 40: 34-38.
[9]	Zhang F, Liu L, Zhang C, et al. Association of Metabolic Syndrome and Its Components With Risk of Stroke Recurrence and Mortality: A Meta-analysis [J]. Neurology, 2021, 97(7): e695-e705.
[10]	Cho JH, Rhee EJ, Park SE, et al. The Risk of Myocardial Infarction and Ischemic Stroke According to Waist Circumference in 21 749 261 Korean Adults: A Nationwide Population-Based Study [J]. Diabetes Metab J, 2019, 43(2): 206-221.
[11]	Liu X, Zhang D, Liu Y, et al. A J-shaped relation of BMI and stroke: Systematic review and dose-response meta-analysis of 4.43 million participants [J]. Nutr Metab Cardiovasc Dis, 2018, 28(11): 1092-1099.
[12]	Chen W, Pan Y, Jing J, et al. Recurrent Stroke in Minor Ischemic Stroke or Transient Ischemic Attack With Metabolic Syndrome and/or Diabetes Mellitus [J]. J Am Heart Assoc, 2017, 6(6): e005446.
[13]	Huang Q, Yin L, Liu Z, et al. Association of novel lipid indicators with the risk of stroke among participants in Central China: a population-based prospective study [J]. Front Endocrinol (Lausanne). 2023.14:1266552.
[14]	Liu Z, Huang Q, Deng B, et al. Elevated Chinese visceral adiposity index increases the risk of stroke in Chinese patients with metabolic syndrome [J]. Front Endocrinol (Lausanne), 2023, 14: 1218905.
[15]]	Bauersachs R, Zeymer U, Brière JB, et al. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review [J]. Cardiovasc Ther, 2019, 2019: 8295054.
[16]	Soriano-Moreno DR, Fernandez-Morales J, Medina-Ramirez SA, et al. Metabolic Syndrome and Risk of Peripheral Arterial Disease: A Systematic Review and Meta-Analysis [J]. Cardiol Rev, 2022.
[17]	Gami A, Witt B, Howard D, et al. Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death: A Systematic Review and Meta-Analysis of Longitudinal Studies [J]. J Am Coll Cardiol, 2007, 49(4): 403-414.
[18]	Maksimovic M, Vlajinac H, Radak D, et al. Relationship between peripheral arterial disease and metabolic syndrome [J]. Angiology, 2009, 60(5): 546-553.
[19]	Gao L, Zhao W, Liu Q, et al. Association Between Metabolic Syndrome and Peripheral Arterial Disease in Elderly Patients with Type 2 Diabetes [J]. Diabetes Metab Syndr Obes, 2021, 14: 4783-4789.
[20]	Chen Q, Zhu H, Shen F, et al. Sex-influenced association of metabolic syndrome with lower extremity arterial disease in type 2 diabetes [J]. J Diabetes Complications, 2020, 34(5): 107537.
[21]	Masenga SK, Kabwe LS, Chakulya M, et al. Mechanisms of Oxidative Stress in Metabolic Syndrome [J]. Int J Mol Sci, 2023, 24(9): 7898.
[22]	Aboonabi A, Meyer RR, Singh I. The association between metabolic syndrome components and the development of atherosclerosis [J]. J Hum Hypertens, 2019, 33(12): 844-855.
[23]	Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? [J]. Diabetologia, 2015, 58(5): 886-899.
[24]	Förstermann U, Xia N, Li H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis [J]. Circ Res, 2017, 120(4): 713-735.
[25]	Mitra R, O'Neil GL, Harding IC, et al. Glycocalyx in Atherosclerosis-Relevant Endothelium Function and as a Therapeutic Target [J]. Curr Atheroscler Rep, 2017, 19(12): 63.
[26]	Förstermann U, Xia N, Li H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis [J]. Circ Res, 2017, 120(4): 713-735.
[27]	Torres S, Fabersani E, Marquez A, et al. Adipose tissue inflammation and metabolic syndrome. The proactive role of probiotics [J]. Eur J Nutr, 2019, 58(1): 27-43.
[28]	Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease [J]. J Clin Invest, 2017, 127(1): 1-4.
[29]	Wu J, He S, Song Z, et al. Macrophage polarization states in atherosclerosis [J]. Front Immunol, 2023, 14: 1185587.
[30]	Zhang S, Gang X, Yang S, et al. The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases [J]. Front Immunol, 2021, 12: 678355.
[31]	Kang SG, Piniecki RJ, Hogenesch H, et al. Identification of a Chemokine Network That Recruits FoxP3+ Regulatory T Cells Into Chronically Inflamed Intestine [J]. Gastroenterology, 2007, 132(3): 966-981.
[32]]	van Diepen JA, Berbée JF, Havekes LM, et al. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis [J]. Atherosclerosis, 2013, 228(2): 306-315.
[33]	O'Neill BJ. Effect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome [J]. Curr Opin Endocrinol Diabetes Obes, 2020, 27(5): 301-307.
[34]	Stanek A, Brożyna-Tkaczyk K, Zolghadri S, et al. The Role of Intermittent Energy Restriction Diet on Metabolic Profile and Weight Loss among Obese Adults [J]. Nutrients, 2022, 14(7): 1509.
[35]	Xu R, Cao Y, Wang PY, et al. Intermittent energy restriction vs. continuous energy restriction on cardiometabolic risk factors in patients with metabolic syndrome: a meta-analysis and systematic review [J]. Front Nutr, 2023, 10: 1090792.
[36]	Alkhulaifi F, Darkoh C. Meal Timing, Meal Frequency and Metabolic Syndrome [J]. Nutrients, 2022, 14(9): 1719.
[37]	Franczyk B, Gluba-Brzózka A, Ciałkowska-Rysz A, et al. The Impact of Aerobic Exercise on HDL Quantity and Quality: A Narrative Review [J]. Int J Mol Sci, 2023, 24(5): 4653.
[38]	Battista F, Ermolao A, van Baak MA, et al. Effect of exercise on cardiometabolic health of adults with overweight or obesity: Focus on blood pressure, insulin resistance, and intrahepatic fat-A systematic review and meta-analysis [J]. Obes Rev, 2021, 22(Suppl 4): e13269.
[39]	Bray GA, Greenway FL. Pharmacological treatment of the overweight patient [J]. Pharmacol Rev, 2007, 59(2): 151-184.
[40]	Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity [J]. Trends Cardiovasc Med, 2023, 33(3): 159-166.
[41]	Merćep I, Vujević A, Strikić D, et al. Present and Future of Dyslipidaemia Treatment-A Review [J]. J Clin Med, 2023, 12(18): 5839.
[42]	Katsimardou A, Imprialos K, Stavropoulos K, et al. Hypertension in Metabolic Syndrome: Novel Insights [J]. Curr Hypertens Rev, 2020, 16(1): 12-18.
[43]	Castrejón-Téllez V, Villegas-Romero M, Rubio-Ruiz ME, et al. Effect of a Resveratrol/Quercetin Mixture on the Reversion of Hypertension Induced by a Short-Term Exposure to High Sucrose Levels Near Weaning and a Long-Term Exposure That Leads to Metabolic Syndrome in Rats [J]. Int J Mol Sci, 2020, 21(6): 2231.
[44]	Villegas Vílchez LF, Ascencios JH, Dooley TP. GlucoMedix®, an extract of Stevia rebaudiana and Uncaria tomentosa, reduces hyperglycemia, hyperlipidemia, and hypertension in rat models without toxicity: a treatment for metabolic syndrome [J]. BMC Complement Med Ther, 2022, 22(1): 62.
[45]	Chandrakumar H, Khatun N, Gupta T, et al. The Effects of Bariatric Surgery on Cardiovascular Outcomes and Cardiovascular Mortality: A Systematic Review and Meta-Analysis [J]. Cureus, 2023, 15(2): e34723.
[46]	Ardissino M, Watson F, Amin R, et al. Atherosclerotic disease burden after bariatric surgery in patients with obesity and type 2 diabetes [J]. J Diabetes, 2021, 13(8): 640-647.
[47]	Yang W, Zhan M, Li Z, et al. Major Adverse Cardiovascular Events Among Obese Patients with Diabetes After Metabolic and Bariatric Surgery: a Meta-analysis of Matched Cohort and Prospective Controlled Studies with 122,361 Participates [J]. Obes Surg, 2023, 33(7): 2098-2107.
[48]	Arias A, Rodríguez-álvarez C, González-Dávila E, Acosta-Torrecilla A, Novo-Muñoz MM, Rodríguez-Novo N. Arterial Hypertension in Morbid Obesity after Bariatric Surgery: Five Years of Follow-Up, a Before-And-After Study [J]. Int J Environ Res Public Health, 2022, 19(3): 1575.
[49]	Valera RJ, Sarmiento-Cobos M, Montorfano L, et al. The impact of bariatric surgery on hospitalization due to peripheral artery disease and critical limb ischemia: a nationwide analysis [J]. Surg Obes Relat Dis. 2023, 19(10):1162-1168.
[50]	Moussa O, Ardissino M, Muttoni S, et al. Long-term incidence and outcomes of obesity-related peripheral vascular disease after bariatric surgery [J]. Langenbecks Arch Surg, 2021, 406(4): 1029-1036.
[51]	Kirwan JP, Courcoulas AP, Cummings DE, et al. Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) [J]. Diabetes Care, 2022, 45(7): 1574-1583.
[52]	杨华, 张鹏, 董志勇, 等. 中国肥胖代谢外科手术方式推荐立场声明 [J/CD]. 中华肥胖与代谢病电子杂志, 2021, 7(1): 8-12.

Please choose a citation manager

Content to export